phenomena and Respiratory Syncytial Virus (RSV), and these low temps can make it harder for your immune system to fight off ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

He proposed exempting Social Security benefits from income tax, which would effectively raise benefits for those ...

In addition, annual estimates of RSV-associated ICU admissions ranged from 24,400 to 34,900 for the 2016-2017 and 2017-2018 ...

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations ...

Residents should get flu and COVID-19 shots, and those who qualify should be immunized against RSV, state officials said.

Moderna said on Friday that Canada’s health regulator has approved its vaccine for respiratory syncytial virus (RSV) in adults 60 years and older, making it the country’s first authorized mRNA ...